Flash Finance

Krsnaa Diagnostics LimitedKRSNAACorporate

Healthcare Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹533.30
MCap ₹1,730 Cr · P/E 17.7
Krsnaa Diagnostics Limited — Stock analysis & AI research Krsnaa Diagnostics Limited — Multibagger AI analysis Krsnaa Diagnostics Limited — Seasonality — best & worst months Krsnaa Diagnostics Limited — Technical indicators & charts Krsnaa Diagnostics Limited — Technical setup — score, trend, support & resistance Krsnaa Diagnostics Limited — Live exchange announcements
📋 High Operating Margin Stocks 📈 Bollinger Squeeze Stocks📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹236 Cr
Sales · Jun 2026
+22.1% YoY
₹58 Cr
Operating Profit · Jun 2026
+12.8% YoY
24.6%
OPM % · Jun 2026
-7.5% YoY
₹17 Cr
Net Profit · Jun 2026
-19.3% YoY
₹5.10
EPS · Jun 2026
-19.7% YoY

📝 Krsnaa Diagnostics Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Krsnaa Diagnostics Limited reported revenue of ₹236 crore for the quarter ended June 2026 (Q1 FY27), up 22.1% from ₹193 crore in the same quarter last year, and up 22.0% sequentially over the March 2026 quarter.

Net profit fell 19.3% year-on-year to ₹17 crore, from ₹21 crore. Earnings per share (EPS) came in at ₹5.10.

Operating profit stood at ₹58 crore — an operating margin (OPM) of 24.6%, compared with 26.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Krsnaa Diagnostics Limited posted revenue of ₹773 crore, a growth of 7.8% over FY25, with a net profit of ₹102 crore (up 31.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹816 crore with a net profit of ₹98 crore.

Valuation snapshot

At the current price of ₹533.30, KRSNAA has a market capitalisation of ₹1,730 crore and a trailing P/E of about 17.7.

Within the Healthcare industry, it is the 9th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 27.11%, foreign institutional investors (FIIs) 3.84%, domestic institutional investors (DIIs) 14.50%, public shareholders 54.54% of Krsnaa Diagnostics Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,730 Cr
Current Price ?
₹533.3
P/E ?
17.70below ind
Industry P/E ?
34.70
P/B ?
1.77
P/S ?
2.12
P/FCF ?
-24.03
Enterprise Value ?
₹2,264 Cr
EV/EBITDA ?
10.36
PEG ?
0.98
Earnings Yield ?
5.4%
Dividend Yield ?
0.51%
Profitability & Returns
Sales (TTM) ?
₹816 Cr
OPM ?
26.8%
Profit after tax (TTM) ?
₹98 Cr
EPS (TTM) ?
₹30.13
ROCE ?
13.0%
ROE ?
10.0%
ROA ?
5.4%
Growth
Sales — latest qtr ?
₹236 Cr
PAT — latest qtr ?
₹17 Cr
YoY qtr sales growth ?
22.1%
YoY qtr profit growth ?
-19.3%
Sales growth (3y) ?
17%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
18%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹534 Cr
Debt to Equity ?
0.54
Interest Coverage ?
3.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
27.11%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-1.2%
Return 6 months ?
-14.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 118133140155158166170186175186193206181193236 +22.1% +22.0%
Operating Profit 293431323744434945535159465558 +12.8% +5.4%
Other Income 5644447594444327 +83.3% -77.4%
Interest 22234756676881215 +135.5% +23.6%
Depreciation 141516192118212223222224232328 +29.2% +21.5%
Profit Before Tax 182418131623232525292732205222 -18.2% -56.9%
Net Profit 141915101319182019212124154217 -19.3% -60.6%
EPS 4.356.034.663.354.095.805.556.076.016.406.357.384.7212.865.10 -19.7% -60.3%
OPM % 24.9% 25.9% 22.5% 20.4% 23.6% 26.3% 25.1% 26.5% 25.8% 28.5% 26.6% 28.7% 25.6% 28.5% 24.6% -7.5% -13.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹717 Cr ₹773 Cr ₹816 Cr +7.8%
Operating Profit ₹190 Cr ₹212 Cr ₹219 Cr +11.5%
OPM % 26.51% 27.42% 26.80% +3.4%
NPM % 10.82% 13.16% 11.98% +21.6%
Other Income ₹26 Cr ₹44 Cr ₹47 Cr +71.9%
Depreciation ₹88 Cr ₹91 Cr ₹97 Cr +2.9%
Interest ₹25 Cr ₹34 Cr ₹43 Cr +39.1%
EBIT ₹102 Cr ₹121 Cr ₹121 Cr +19.0%
PBT ₹103 Cr ₹131 Cr ₹126 Cr +27.2%
Tax ₹25 Cr ₹19 Cr ₹18 Cr -24.4%
Net Profit ₹78 Cr ₹102 Cr ₹98 Cr +31.0%
EPS ₹24.03 ₹31.31 ₹30.06 +30.3%
Material Cost ₹169 Cr ₹135 Cr ₹137 Cr -20.4%
Employee Cost ₹137 Cr ₹107 Cr ₹108 Cr -21.7%
Extraordinary Items — — ₹0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 16161616 +0.0%
Reserves 723794867964 +11.2%
Borrowings 32160204534 +161.8%
Other Liabilities 137201192309 +60.9%
Total Liabilities 9081,1701,2781,824 +42.7%
Fixed Assets 471647670656 -2.1%
CWIP 25103208 +6833.3%
Investments 003257 +78.1%
Other Assets 412513573902 +57.4%
Total Assets 9081,1701,2781,824 +42.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 762487143 +64.4%
Cash from Investing Activity -109-129-100-396 -296.0%
Cash from Financing Activity -338414279 +1892.9%
Net Cash Flow -66-20126 +2500.0%
Free Cash Flow -58-169-24-72 -200.0%
CFO/OP 73%30%56%81% +44.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 55104141140 -0.7%
Inventory Days ———54 —
Days Payable ———129 —
Cash Conversion Cycle 5510414165 -53.9%
Working Capital Days 11-212148 +128.6%
ROCE % 12%10%12%13% +8.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 27.11%27.11%27.11%27.11%27.11% +0.0%
FIIs 3.40%3.66%4.17%3.91%3.84% -1.8%
DIIs 14.24%14.96%13.85%13.89%14.50% +4.4%
Public 55.25%54.27%54.86%55.09%54.54% -1.0%
No. of Shareholders 54,26252,11752,38053,02250,671 -4.4%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Krsnaa Diagnostics Limited's revenue in Q1 FY27?
Krsnaa Diagnostics Limited reported revenue of ₹236 crore for the quarter ended June 2026 (Q1 FY27), up 22.1% from ₹193 crore in the same quarter last year, and up 22.0% sequentially over the March 2026 quarter.
What was Krsnaa Diagnostics Limited's net profit in Q1 FY27?
Net profit fell 19.3% year-on-year to ₹17 crore, from ₹21 crore. Earnings per share (EPS) came in at ₹5.10.
What is KRSNAA's market capitalisation and P/E ratio?
At the current price of ₹533.30, KRSNAA has a market capitalisation of ₹1,730 crore and a trailing P/E of about 17.7.
Who owns Krsnaa Diagnostics Limited? (shareholding pattern)
As of Sep 2026, promoters held 27.11%, foreign institutional investors (FIIs) 3.84%, domestic institutional investors (DIIs) 14.50%, public shareholders 54.54% of Krsnaa Diagnostics Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI